Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company

Merck KGaA Launches First GMP Cell Culture Medium Production Line in China

Fineline Cube Jul 15, 2024

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of...

Company Deals

AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137

Fineline Cube Jul 15, 2024

AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...

Company Drug

Mabwell Bioscience’s 9MW2821 Earns FDA Fast Track Designation for Triple Negative Breast Cancer

Fineline Cube Jul 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China

Fineline Cube Jul 15, 2024

Shanghai Duoning Biotechnology Co., Ltd, a prominent player in China’s biopharmaceutical industry, has entered into...

Company Drug

NMPA Accepts 3SBio’s Filing for Anemia Treatment SSS06, Potential Game Changer for Dialysis Patients

Fineline Cube Jul 15, 2024

3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that the...

Company Deals

Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences

Fineline Cube Jul 15, 2024

China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment...

Company Deals Drug

Huadong Medicine Secures Exclusive Rights to Oral Edaravone Candidate TTYP01 in Major Licensing Deal

Fineline Cube Jul 15, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into...

Company Drug

Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma

Fineline Cube Jul 15, 2024

Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...

Company Deals

Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit

Fineline Cube Jul 15, 2024

Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...

Company R&D

Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits

Fineline Cube Jul 15, 2024

Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...

Company Drug

Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China

Fineline Cube Jul 12, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...

Company Deals R&D

Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery

Fineline Cube Jul 12, 2024

Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in...

Company Drug

Jiangsu Hengrui’s Subsidiary Conducts First Surgical Dosing in Parkinson’s Gene Therapy Clinical Trial

Fineline Cube Jul 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Medical Device

Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities

Fineline Cube Jul 12, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent...

Company Drug

Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401

Fineline Cube Jul 12, 2024

Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...

Company Deals

Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001

Fineline Cube Jul 12, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...

Company Drug

Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong

Fineline Cube Jul 12, 2024

Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...

Company Drug

Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity

Fineline Cube Jul 12, 2024

Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...

Company Drug

Novo Nordisk’s Awiqli Faces FDA Setback as BLA Draws Complete Response Letter

Fineline Cube Jul 12, 2024

Novo Nordisk A/S (NYSE: NVO) announced that the U.S. Food and Drug Administration issued a...

Company Drug

CSPC Pharmaceutical’s RSV mRNA Vaccine SYS6016 Receives Clinical Trial Approval from NMPA

Fineline Cube Jul 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Posts pagination

1 … 326 327 328 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.